Lilly drug cuts risk of disease progression or death by 80% in trial

The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Agilent and Monash Malaysia launch cutting-edge BioDiscovery hub to boost regional biotech

The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub

Agilus Diagnostics launches comprehensive obesity & metabolic health test suite

The Vital Shape panels provide tiered assessments to detect obesity-related risks early

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development

Eurofins launches first GMP PFAS testing solution for medical devices

Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension

Here's a development that aims to keep your blood pressure in check. Literally!

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease

Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss